IMUTHIOL, A T-CELL SPECIFIC IMMUNOPOTENTIATOR NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IMUTHIOL, A T-CELL SPECIFIC IMMUNOPOTENTIATOR

Int J Immunotherapy; 6(1):25-35 1990. Unique Identifier : AIDSLINE ICDB/92669937
Renoux G; Renoux M; Immunology Lab., Faculty of Medicine, 37032 Tours, France

Abstract: Imuthiol (Institut Merieux, Lyon, France), purified sodium diethyldithiocarbamate (Ditiocarb, DTC), evinces distinctive properties, not actually shared by other biologicals. Imuthiol recruits T cells from precursors and activates T-cell functions, including interleukin-2 production and NK activity, without time- and dose-dependent inhibitory effects. It modifies MHC-encoded antigens on the T-cell surface. Imuthiol is also an anti-inflammatory agent; its mechanisms of action involve a brain neocortex control. Imuthiol regulates microsomal enzyme activities. It inhibits metalloenzymes in microorganisms or neoplastic cells without affecting normal mammalian cells. It protects against the toxicities of chemicals, and it has antibiotic effects. Imuthiol improves the clinical status and restores T-cell numbers and functions in patients (pts) affected with ailments associated with T-cell deficit or dysfunction (elderly, chronic infection, tuberculosis, surgery, cancer, autoimmune diseases, etc), without untoward effects. Importantly, Imuthiol inhibits HIV reverse transcriptase. It increases the CD4+ population and induces long-lasting clinical improvement in pts with AIDS-related complex. Thus, Imuthiol, a non-toxic and T-cell specific immunopotentiator, can be used to treat pts with incipient HIV infection. (62 Refs)
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY Adult Aged Animal AIDS-Related Complex/DRUG THERAPY Child Ditiocarb/*THERAPEUTIC USE Dose-Response Relationship, Drug Double-Blind Method Human Immunologic Deficiency Syndromes/*DRUG THERAPY Neoplasms/DRUG THERAPY Opportunistic Infections/DRUG THERAPY T-Lymphocytes/*DRUG EFFECTS JOURNAL ARTICLE CLINICAL TRIAL MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL REVIEWKWDacquiredimmunodeficiencysyndrome/drugtherapyadultagedanimalaids-relatedcomplex/drugtherapychildditiocarb/KWDtherapeuticusedose-responserelationship,drugdouble-blindmethodhumanimmunologicdeficiencysyndromes/KWDdrugtherapyneoplasms/drugtherapyopportunisticinfections/drugtherapyt-lymphocytes/KWDdrugeffectsjournalarticleclinicaltrialmulticenterstudyrandomizedcontrolledtrialreview
921230
M92C5383

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .